Intravitreal use of bevacizumab (Avastin) for choroidal neovascularization due to ARMD: a preliminary multifocal-ERG and OCT study
To evaluate by MFERG and OCT the macular function before and after intravitreal use of bevacizumab (Avastin) in eyes suffering from CNV due to ARMD.
Eighteen eyes with subfoveal CNV due to ARMD were studied before and after intravitreal use of bevacizumab with MFERG and OCT. The post treatment follow up was three months.
Before treatment, OCT shows an increase of the retinal thickening of the fovea and the electrical response densities in the fovea and parafovea were decreased in all patients. Three months after treatment, OCT showed a real resolution of the subretinal fluid. The electrical responses in the fovea and parafovea remained the same or slightly improved in some cases. The intraocular pressure remained normal and no inflammation was observed.
The intravitreal use of bevacizumab may provide anatomical correlates that support the concept of disease amelioration but the functional improvement of the macula three months after treatment is not obvious. However the method is promising and needs further evaluation.
KeywordsAge related macular degeneration (ARMD) Bevacizumab (Avastin) Choroidal neovascularization (CNV) Multifocal Electroretinogram (MFERG) Optical Coherence Tomography (OCT)
- 5.Macular Photocoagulation Study Group. (1991) Subfoveal neovascular lesions in age related macular degeneration. Guidelines for evaluation and treatment in the macular photocoagulation study. Arch Ophthalmol 109:1242–1257Google Scholar
- 6.Verteporfin in photodynamic therapy Study Group (2001) Vertyeporfin therapy of subfoveal choroidal neovascularisation in age related macular degeneration: two years results of randomized clinical trials including lesions with occult or classic choroidal neovasularisation-verteporfin in photodynamic therapy report 2. Am J Ophthalmol 131:541–560CrossRefGoogle Scholar
- 7.TAP Study Group (2001) Photodynamic therapy of subfoveal choroidal neovascularisation in age related macular degeneration with Verteporfin: two years results of 2 randomized clinical trials-TAP Report 2. Arch Ophthalmol 119:198–207Google Scholar
- 13.Rosenfeld PJ, Moshfeghi AA, Puliafito CA et al (2005) Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age related macular degeneration. Ophthalmic Surg Lasers Imaging 36:270–271Google Scholar